Language
Open app

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

Why it matters

Attributed market update with source link for portfolio context.

Sources

Attributed news only. Not investment advice.

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? | TahmVest News · TahmVest